Amphista Therapeutics, a next-generation targeted protein degradation specialist, has appointed Antony Mattessich as its CEO and member of its Board of Directors.
Antony is an experienced CEO, who has worked to progress programmes in drug discovery, clinical development and commercialisation.
He has raise over USD $750m for companies throughout his career, and has held a number of senior executive positions in pharmaceutical companies.
Before his appointment at Amphista, Antony was the President and CEO of Ocular Therapeutix, where he was instrumental in the launch of the company's lead asset, as well as bringing a wet-AMD therapeutic from preclinical to Phase III trials.
Joshua Brumm, Chair of Amphista’s Board of Directors said: “Antony’s extensive drug development and capital markets expertise are a perfect fit for Amphista as we plan to advance our lead assets into clinical development following the compelling new in vivo efficacy and CNS activity data announced this year. We are delighted to have someone with Antony’s leadership and track record joining at such a transformational time for Amphista.”
In January 2024, the Company announced the achievement of two new data sets with its next generation bifunctional non-cereblon / non-VHL-based protein degraders. This was followed in May 2024 by the unveiling of a new mechanism of action for the degradation of BRD9, an emerging target in oncology, that is differentiated from cereblon- or VHL-based PROTACs.
